Benefits of 177Lu-DOTATATE in Patients with Advanced Neuroendocrine Tumours: Case Reports from Two Patients with High Disease Burden
Introduction: In the NETTER-1 study, peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE increased progression-free survival (PFS) and time to deterioration in quality of life (QoL) in patients with advanced midgut neuroendocrine tumours (NETs), compared with octreotide.
Aim(s): To report outcomes (including QoL) of two male patients aged 49 years with advanced, metastatic NETs treated with 177Lu-DOTATATE.
Materials and methods: Patient A had a midgut NET (grade 2; Ki-67: 5–10%) with liver, mesenteric node and likely bone metastases. He received treatment with a somatostatin analogue (SSA). Patient B had a pancreatic NET (grade 2; Ki-67: 18%). After resection, the NET recurred with extensive liver metastases and became insulin-secreting. The patient successively received an SSA, chemotherapy, everolimus and liver embolization. Continuous dextrose infusion was used to prevent hypoglycaemia. Both patients subsequently received PRRT with four cycles of 177Lu-DOTATATE.
Conference: 17th Annual ENETSConcerence (2020)
To read the full abstract, please log into your ENETS Member account.